BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go ...

Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland ...

Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings ...

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...

As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of ...

Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Faced with potential monetary fines, Johnson & Johnson said Monday it is abandoning a proposed 340B rebate plan for hospitals ...

Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not ...